AB Science SA
PAR:AB

Watchlist Manager
AB Science SA Logo
AB Science SA
PAR:AB
Watchlist
Price: 1.46 EUR -4.95% Market Closed
Market Cap: 96.6m EUR

AB Science SA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AB Science SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
AB Science SA
PAR:AB
Cash from Operating Activities
-€6.9m
CAGR 3-Years
27%
CAGR 5-Years
11%
CAGR 10-Years
11%
Sanofi SA
PAR:SAN
Cash from Operating Activities
€11.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Cash from Operating Activities
€897.2m
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
15%
Vetoquinol SA
PAR:VETO
Cash from Operating Activities
€70.9m
CAGR 3-Years
16%
CAGR 5-Years
-2%
CAGR 10-Years
6%
Virbac SA
PAR:VIRP
Cash from Operating Activities
€196.2m
CAGR 3-Years
33%
CAGR 5-Years
6%
CAGR 10-Years
10%
Medincell SA
PAR:MEDCL
Cash from Operating Activities
-€18m
CAGR 3-Years
3%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

AB Science SA
Glance View

Market Cap
87.6m EUR
Industry
Pharmaceuticals

AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

AB Intrinsic Value
0.07 EUR
Overvaluation 95%
Intrinsic Value
Price

See Also

What is AB Science SA's Cash from Operating Activities?
Cash from Operating Activities
-6.9m EUR

Based on the financial report for Jun 30, 2025, AB Science SA's Cash from Operating Activities amounts to -6.9m EUR.

What is AB Science SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
11%

Over the last year, the Cash from Operating Activities growth was -57%. The average annual Cash from Operating Activities growth rates for AB Science SA have been 27% over the past three years , 11% over the past five years , and 11% over the past ten years .

Back to Top